ROCKVILLE,
Md., Nov. 7, 2023 /PRNewswire/ -- REGENXBIO
Inc. (Nasdaq: RGNX) today announced it will participate the
following upcoming investor conferences:
Stifel 2023 Healthcare
Conference
Fireside Chat Date: Tuesday, November 14, 2023
Fireside Chat Time: 3:00 p.m.
ET
Location: New York, NY
Piper Sandler
35th Annual Healthcare
Conference
Fireside Chat Date: Wednesday, November 29, 2023
Fireside Chat Time: 12:30 p.m.
ET
Location: New York, NY
A live webcast of the fireside chats can be
accessed in the Investors section of REGENXBIO's website at
www.regenxbio.com. An archived replay of the webcast will be
available for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage
biotechnology company seeking to improve lives through the curative
potential of gene therapy. REGENXBIO's NAV Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301979626.html
SOURCE REGENXBIO Inc.